Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a significant milestone for the company and is the first product they've had approved by a regulator. ''Backing that up we've got a number of other products, one I'm particularly excited about, which we're developing for the treatment of cancer as well as one for migraine and also a couple of products in the medical cannabis space''.
Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead product ZolpiMist
Quick facts: SUDA Pharmaceuticals Ltd
Price: 0.042 AUD
Market Cap: $12.89 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE